[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-276180-105":3,"detail-sidebar-cat-1-en-105":73,"doc-detail-276180-en":119},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","provider-appeal-letter-template-litfulo","Provider Appeal Letter Template - Litfulo","","Provider appeal letter template requesting an insurance provider to reconsider a denial of coverage for Litfulo for a patient diagnosed with alopecia areata. The letter frames alopecia areata as an autoimmune condition causing unpredictable hair loss and associated distress, then argues medical necessity based on limited prior options and Litfulo’s evidence-supported efficacy. It cites clinical trials and safety data and requests coverage to improve both physical and mental well-being while potentially reducing long-term healthcare burdens.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/letters/","Letters",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/provider-appeal-letter-template-litfulo/276180/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/provider-appeal-letter-template-litfulo/276180.png","ImageObject",442,249,{"name":42,"@type":43},"Terk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-19","2026-09-15",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"What information should be included from the patient’s side?","Question",{"text":63,"@type":64},"The template requires the patient’s full name and prior treatments/results, and it includes sections for provider contact details and references to supporting clinical studies.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},276180,1790146305,{"code":4,"msg":74,"data":75},"success",[76,81,86,91,96,101,106,110,115],{"id":77,"doc_module":22,"doc_module_name":25,"category_name":78,"show_sort_weight":79,"slug":80},11,"Presentations",90,"presentations",{"id":82,"doc_module":22,"doc_module_name":25,"category_name":83,"show_sort_weight":84,"slug":85},12,"Resumes",80,"resumes",{"id":87,"doc_module":22,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},14,"Invoices",70,"invoices",{"id":92,"doc_module":22,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},15,"Posters",60,"posters",{"id":97,"doc_module":22,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},16,"Social Media",50,"social-media",{"id":102,"doc_module":22,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},17,"Forms",40,"forms",{"id":107,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},18,30,"letters",{"id":111,"doc_module":22,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},21,"Paper Templates",5,"papers-templates",{"id":116,"doc_module":22,"doc_module_name":25,"category_name":117,"show_sort_weight":4,"slug":118},158,"General","general-158",{"code":4,"msg":74,"data":120},{"doc_id":71,"user_id":121,"nickname":42,"user_avatar":122,"doc_module":22,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":123,"file_id":124,"file_url":125,"file_type":126,"file_size":127,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":128,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":129,"faqs":130,"seo_title":131,"seo_description":12,"update_tm":132,"read_time":22},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","PROVIDER APPEAL TEMPLATE FOR LITFULO  \n[Your Name]  \n[Your Title]  \n[Your Address][City, State, Zip Code][Phone Number][Email Address][Date]  \nClaims Department  \n[Insurance Company Name]  \n[Insurance Company Address][City, State, Zip Code]  \nDear Claims Review Team,  \nRe: Request for Coverage of Litfulo ( ritleciOnib ) for Treatment of Alopecia Areata  \nI am writing to formally request that [Insurance Company Name] reconsider its decision to deny coverage for Litfulo ( ritleciOnib ) for my patient, [Patient’s Full Name], who has been diagnosed with alopecia areata. As you are aware, alopecia areata is an autoimmune disease that causes unpredictable and often distressing hair loss, and it can significantly impact the mental and emotional well-being of those affected. After careful evaluation and treatment consideration, Litfulo has been prescribed as an appropriate therapeutic option for this patient’s condition.  \nMedical Necessity of Litfulo for Alopecia Areata  \nAlopecia areata is a chronic, autoimmune disease in which the immune system mistakenly attacks hair follicles, leading to hair loss. Treatment options have been limited, and many existing therapies have suboptimal efficacy, side effects, or both.  \n[Include patient’s previous treatments/results here}  \nLitfulo is the second Janus kinase inhibitor (JAK inhibitor) to receive FDA approval for severe alopecia areata. It is indicated for patients 12 years of age and older, and offers an effective treatment for managing alopecia areata. Recent clinical trials and studies have demonstrated Litfulo’s ability to promote hair regrowth in patients with moderate to severe alopecia areata.  \nThis evidence supports the fact that Litfulo is not only a safe and effective treatment for alopecia areata but also represents a medically necessary option for patients who have not responded well to other therapies. Additionally, by improving the quality of life for patients and reducing the psychological burden of alopecia areata, Litfulo may help mitigate the long-term healthcare costs associated with mental health treatment and therapy.  \nThe treatment plan for [Patient’s Full Name] includes Litfulo as a medically necessary intervention to control the progression of alopecia areata, encourage hair regrowth, and improve the patient’s quality of life. Given the distressing nature of this condition, the psychological impact of visible hair loss, and the failure of prior treatment options, Litfulo represents a necessary and appropriate option for achieving optimal therapeutic outcomes.  \nIn light of the substantial clinical evidence supporting Litfulo’s efficacy and safety profile, as well as its potential to improve both the physical and mental health of patients with alopecia areata, I respectfully request that [Insurance Company Name] reconsider its denial of coverage for this treatment. Given the unique challenges posed by alopecia areata, Litfulo offers a medically necessary and effective option for managing this condition, and it is essential for improving the patient’s quality of life.  \nThank you for your time and consideration of this request. Please do not hesitate to contact me if you require any further information or clarification.  \nSincerely,  \n[Your Name]  \n[Your Title]  \n[Your Contact Information]  \nAddiOonal references:  \nKing, Brett, et al. \"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. \" The Lancet 401.10387  \n(2023): 1518-1529.  \nKing, Brett, et al. \"Integrated safety analysis of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. \"  \nAmerican Journal of Clinical Dermatology 25.2 (2024): 299-314.  \nHordinsky, Maria, et al. \"Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. \"Pediatric D","cbCaiq9OQMAPxJPP","https://ap.wps.com/l/cbCaiq9OQMAPxJPP","pdf",29433,"English","# Provider Appeal Letter Template for Litfulo\n## Request for Coverage\n## Medical Necessity and Evidence\n## Treatment Plan and Closing","[{\"question\":\"What information should be included from the patient’s side?\",\"answer\":\"The template requires the patient’s full name and prior treatments/results, and it includes sections for provider contact details and references to supporting clinical studies.\"}]","Provider Appeal Letter Template - Litfulo | PDF",1789491801]